Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Immersive Virtual Reality (VR) at the Time of Clinical Evaluation to Improve Psychological Distress and Anxiety in Primary Brain Tumor (PBT) Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04301089
Recruitment Status : Not yet recruiting
First Posted : March 9, 2020
Last Update Posted : April 7, 2020
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )

Brief Summary:

Background:

Distress, anxiety, and other psychological disorders may be more common in people with primary brain tumors (PBTs). PBTs can affect their symptoms and quality of life. PBTs can also affect their tolerance of cancer treatments. Researchers want to learn if virtual reality (VR) technology can help. VR uses computer technology to make fake experiences and environments that look real. It lets people escape from their lives and experience more positive

thoughts and emotions.

Objective:

To learn if it is feasible to use a VR relaxation intervention in people with PBT.

Eligibility:

Adults 18 and older who have a brain tumor and have recently reported psychological distress during their participation in the Natural History Study (NHS), protocol #16C0151

Design:

Participants will give saliva samples at 4 time points. They will fill out 4 questionnaires at 4 times points. These forms are not part of the NHS. The 4 time points are:

before the VR intervention in clinic

after the VR intervention in clinic

1 week later at home

1 month later at home

Participants will get a VR headset. It looks like a thick pair of goggles that goes over the eyes. Participants will view computer-generated environments on this headset.

Participants will have a phone interview 1 week after the VR viewing. It will last 10 to 15 minutes.

This study will also use the forms and questionnaires that the participants fill out as part of the NHS.

Participation lasts 4 to 6 weeks.


Condition or disease Intervention/treatment Phase
Anxiety Device: Pico G2 4K Headset with Applied VR software Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Feasibility Trial Using Immersive Virtual Reality (VR) at the Time of Clinical Evaluation to Improve Psychological Distress and Anxiety in Primary Brain Tumor (PBT) Patients
Estimated Study Start Date : April 10, 2020
Estimated Primary Completion Date : January 1, 2022
Estimated Study Completion Date : January 31, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Experimental intervention
Experimental VR Intervention, Survey or Questionnaire Completion and Sample Submission
Device: Pico G2 4K Headset with Applied VR software
headset worn at time points defined in study




Primary Outcome Measures :
  1. Number of participants who complete the sessions and questionnaires [ Time Frame: End of Study ]
    To describe the feasibility of implementing a VR intervention in a PBT population, including eligibility, accrual, compliance, adverse events, study completion, and participant satisfaction with the intervention


Secondary Outcome Measures :
  1. Measurement of Distress [ Time Frame: End of Study ]
    To assess the effects of a VR intervention on self-reported acute and subacute distress (as measured by the NCCN Distress Thermometer [DT]) and anxiety (as measured by the State Anxiety Inventory [STAI-6]) in PBT patients

  2. Measurement of mood disturbance [ Time Frame: End of Study ]
    To assess the effects of a VR intervention on self-reported mood disturbance (as measured by PROMIS - Anxiety & PROMIS - Depression Short Forms) and symptom burden and interference (as measured by the MD Anderson Symptom Inventory Brain Tumor [MDASI-BT])

  3. Measurement of distress and anxiety [ Time Frame: End of Study ]
    To determine if the effects VR has on distress and anxiety are more pronounced in those with high distress (based on DT cut-off score of greater than or equal to 5) compared those with to low distress (based on DT scores of 0-4)

  4. Measurement and comparison of distress and anxiety on those on systemic corticosteroids [ Time Frame: End of Study ]
    To determine if the effects VR has on distress and anxiety are more pronounced in those individuals not on systemic corticosteroids (CS) compared to those who are



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  • INCLUSION CRITERIA:
  • PBT patients enrolled on the Natural History Study (NHS) trial (16C0151) in the Neuro-Oncology Branch (NOB) who have an upcoming scan & clinical appointment
  • Participants can be newly diagnosed, receiving active treatment, or on surveillance
  • Concurrent enrollment in other NOB trials is permissible
  • Adults (greater than or equal to 18 years of age) who are English-speaking
  • Participants must be able to reliably self-report symptoms, based on clinician assessment
  • Participants report greater than or equal to 1 on distress item from MDASI-BT prior to clinic appointment
  • Active corticosteroid therapy is permissible
  • Ability of subject to understand and the willingness to sign a written informed consent document

EXCLUSION CRITERIA:

  • Participants who do not have a tissue diagnosis (no past surgery or biopsy to confirm diagnosis)
  • Cranial surgery less than or equal to 2 weeks prior to initiation of study intervention
  • Scalp wound healing issues that might interfere with comfortable VR headset use
  • Those who have epilepsy or have had a seizure in the last 6 weeks
  • Participants with a current diagnosis of generalized anxiety disorder, post-traumatic stress disorder, claustrophobia, or panic disorder
  • Participants who have a hypersensitivity to motion or severe nausea, which could make the VR experience uncomfortable
  • Those with visual deficits that might interfere with the VR experience, including hemianopsia, diplopia, and agnosia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04301089


Contacts
Layout table for location contacts
Contact: Sonja K Crandon, R.N. (240) 760-6099 sonja.crandon@nih.gov

Locations
Layout table for location information
United States, Maryland
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office    888-624-1937      
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Terri S Armstrong, C.R.N.P. National Cancer Institute (NCI)

Additional Information:
Publications:
Layout table for additonal information
Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT04301089    
Other Study ID Numbers: 200065
20-C-0065
First Posted: March 9, 2020    Key Record Dates
Last Update Posted: April 7, 2020
Last Verified: March 4, 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) ):
Therapeutic VR Platform
Scanxiety
Brain Cancer
Brain Tumors
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Neoplasms
Anxiety Disorders
Mental Disorders
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Neoplasms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases